Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Short Interest Up 86.7% in December

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) saw a significant growth in short interest in the month of December. As of December 15th, there was short interest totaling 9,599 shares, a growth of 86.7% from the November 30th total of 5,141 shares. Based on an average trading volume of 8,344 shares, the short-interest ratio is presently 1.2 days. Approximately 0.9% of the shares of the company are short sold. Approximately 0.9% of the shares of the company are short sold. Based on an average trading volume of 8,344 shares, the short-interest ratio is presently 1.2 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Addex Therapeutics in a research report on Tuesday, October 14th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Addex Therapeutics has a consensus rating of “Sell”.

Addex Therapeutics Stock Performance

Shares of Addex Therapeutics stock opened at $7.99 on Friday. Addex Therapeutics has a twelve month low of $6.51 and a twelve month high of $12.05. The firm has a market cap of $9.83 million, a P/E ratio of -1.88 and a beta of 1.57. The firm’s 50-day simple moving average is $8.44 and its 200-day simple moving average is $8.60.

Addex Therapeutics (NASDAQ:ADXN) last announced its earnings results on Thursday, December 4th. The company reported ($1.51) earnings per share (EPS) for the quarter. Addex Therapeutics had a negative return on equity of 80.69% and a net margin of 3,584.49%.The firm had revenue of $0.04 million for the quarter.

Addex Therapeutics Company Profile

Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.

The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.